KDR and Hypertension: These authors concluded that among the VEGFR–TKIs, lenvatinib and vandetanib revealed the highest possibility to provoke cardiovascular events and hypertension, followed by cabozantinib, axitinib, pazopanib, sorafenib, sunitinib, regorafenib, and nintedanib.